Allogeneic pASC transplantation in humanized pigs attenuates cardiac remodeling post-myocardial infarction

PLoS One. 2017 Apr 27;12(4):e0176412. doi: 10.1371/journal.pone.0176412. eCollection 2017.

Abstract

Cell therapy repair strategies using adult mesenchymal stromal cells have shown promising evidence to prevent cardiac deterioration in rodents even in the absence of robust differentiation of the cells into cardiomyocytes. We tested whether increasing doses of porcine adipose-tissue derived mesenchymal stem cells (pASCs) increase cardiac tissue perfusion in pigs post-myocardial infarction (MI) receiving angiotensin-converting-enzyme inhibitor (ACE inhibitors) and Beta-blockers similarly to patients. Female pigs were subjected to MI induction by sponge permanent occlusion of left circumflex coronary artery (LCx) generating approximately 10% of injured LV area with minimum hemodynamic impact. We assessed tissue perfusion by real time myocardial perfusion echocardiography (RTMPE) using commercial microbubbles before and following pASCs treatment. Four weeks after the occlusion of the left circumflex artery, we transplanted placebo or pASCs (1, 2 and 4x106 cells/Kg BW) into the myocardium. The highest dose of pASCs increased myocardial vessel number and blood flow in the border (56% and 3.7-fold, respectively) and in the remote area (54% and 3.9-fold, respectively) while the non-perfused scar area decreased (up to 38%). We also found an increase of immature collagen fibers, although the increase in total tissue collagen and types I and III was similar in all groups. Our results provide evidence that pASCs-induced stimulation of tissue perfusion and accumulation of immature collagen fibers attenuates adverse remodeling post-MI beyond the normal beneficial effects associated with ACE inhibition and beta-blockade.

MeSH terms

  • Adipose Tissue / cytology*
  • Animals
  • Coronary Circulation / drug effects
  • Enalaprilat / pharmacology
  • Female
  • Hemodynamics / drug effects
  • Mesenchymal Stem Cell Transplantation*
  • Metoprolol / pharmacology
  • Myocardial Infarction / pathology*
  • Myocardial Infarction / physiopathology
  • Myocardial Infarction / therapy*
  • Swine
  • Transplantation, Homologous
  • Ventricular Remodeling* / drug effects

Substances

  • Metoprolol
  • Enalaprilat

Grants and funding

This work was supported by grants to J.E.K. from Fundação Zerbini; São Paulo Research Foundation [FAPESP 13/17368-0]; Conselho Nacional de Desenvolvimento Científico e Tecnológico [404733-2012-3]; CAPES PROBITEC [23038-4156-2012-80] and Ministério da Saúde do Brasil [MS-DECIT-PROADI_SUS – H. Samaritano]. R.D. was a recipient of a post-doctoral fellowship from FAPESP.